© 2006 WebMD, Inc. All rights reserved.
ACS Surgery: Principles and Practice
2 HEAD AND NECK
2 PAROTID MASS
Ashok R. Shaha, M.D., F.A.C.S.
Approach to Evaluation of a Parotid Mass
There are three major salivary glands in the human body—the
parotid gland, the submandibular gland, and the sublingual
gland—of which the parotid gland is the largest. In addition, there
are approximately 600 to 800 minor salivary glands distributed
throughout the entire upper aerodigestive tract, starting from the
lip and extending to the lower end of the esophagus and up to the
pulmonary alveoli. Almost half of these minor salivary glands are
on the hard palate. Accordingly, any mass on the hard palate
should be considered a minor salivary gland tumor until proved
otherwise.1
The majority of salivary gland tumors originate in the parotid
gland. Approximately 75% to 80% of parotid tumors are
benign.2,3 In the evaluation and surgical treatment of parotid
tumors, it is essential to maintain awareness of the possibility of
temporary or permanent facial nerve injury [see Discussion, Prin-
ciples of Facial Reanimation, below]. Because surgery necessarily
entails some risk of an injury to this structure or its branches, as
well as because most parotid masses do not give rise to significant
symptoms, many patients with parotid tumors may find the
prospect of surgical therapy difficult to accept.
Clinical Evaluation
HISTORY
Evaluation of a parotid mass begins
with a good clinical history. The most
important question is, how long has the
mass been present? If local pain and
swelling of recent onset (i.e., within the
past few days) are reported, infection or
obstruction is the likely cause. If the mass has been present for a
longer period (i.e., weeks to months), a neoplasm is more likely.
Unfortunately, the presentations of some nonneoplastic condi-
tions resemble those of neoplasms, and distinguishing one type of
condition from the other can be challenging. Thus, the history
should continue with further questions focusing on local or sys-
temic signs and symptoms, the presence of swelling or other mass-
es in the salivary glands, and previous medical conditions (includ-
ing skin cancer).
Classification
Major salivary gland masses can be classified as nonneoplastic,
lymphoepithelial, or neoplastic.4
2 PAROTID MASS — 1
Nonneoplastic The causes of nonneoplastic masses include
congenital, granulomatous, infectious or inflammatory, and non-
inflammatory conditions. Some congenital lesions (e.g., heman-
gioma or vascular malformation) present as a vague swelling in the
parotid region that has been present since childhood. One con-
genital lesion, a first branchial cleft cyst, presents as a mass inferi-
or to the cartilaginous ear canal, with a cyst tract that can be either
medial or lateral to the facial nerve and may even divide the trunk
of the nerve. This cyst is most commonly noted in the second
through fourth decades in life.
Granulomatous diseases are frequently manifested by an
asymptomatic, gradual enlargement of a lymph node within the
gland; often, they cannot be readily distinguished from neoplasms.
In sarcoidosis, salivary gland involvement may cause duct obstruc-
tion, pain associated with the duct, xerostomia, or enlargement of
the gland. The diagnosis is supported by chest x-rays that show
bilateral hilar adenopathy and by elevated levels of angiotensin-
converting enzyme (ACE).
As noted (see above), infectious or inflammatory diseases
involving the parotid, unlike neoplasms, tend to give rise to pain in
their early stages. Most such inflammatory conditions begin with
diffuse enlargement of one or more salivary glands. Although
parotitis is generally unilateral, it may be bilateral if a systemic
causative condition is involved, and other salivary glands may be
affected as well.The pain reported may be related to the presence
of a stone in the salivary duct or to diffuse obstructive parotitis.
Chronic parotitis may lead to recurrent infection and inflamma-
tion.When recurrent swelling of the salivary gland does occur, it is
directly related to eating and increased salivation.
Sialadenosis is a noninflammatory, nonneoplastic condition of
unknown origin that is characterized by diffuse enlargement of the
salivary gland, with no discrete mass or inflammation.
Lymphoepithelial Lymphoepithelial lesions may be divided
into lymphocytic infiltrative diseases and lymphomas. In many
cases, patients with lymphocytic infiltrative diseases (e.g., Mikulicz
disease, sicca complex, and Sjögren syndrome) have had their
conditions for long periods, and they may feel that they have
always been chubby, when in fact they have had chronic enlarge-
ment of both parotid glands. In patients with Sjögren syndrome,
malignant transformation to high-grade lymphoma is known to
occur. Lymphoepithelial cysts are benign cystic lesions that may
arise from lymph nodes or from lymphoid aggregates in the sali-
vary gland. These lesions may be associated with HIV infection.
© 2006 WebMD, Inc. All rights reserved. ACS Surgery: Principles and Practice
2 HEAD AND NECK 2 PAROTID MASS — 2

Approach to Evaluation
of a Parotid Mass

Patient presents with parotid mass

Obtain clinical history.

Perform physical examination of parotid region,
focusing on extent of parotid disease, localized
effects of lesion, and any motor or sensory deficits.

Diffuse enlargement is present Solitary mass is identified

Diagnosis is obvious Diagnosis is uncertain

Plan treatment (conservative Initiate further workup:

or surgical, as indicated). • Imaging (CT, MRI, ultrasonography,
sialography, ?sialoendoscopy, ?PET)
• FNA biopsy (routine use is controversial)

Lesion is benign Lesion is malignant

Treat surgically with superficial Treat surgically with superficial, total, or

parotidectomy, preserving radical parotidectomy, as necessary,
facial nerve. preserving facial nerve if possible.
If cervical lymphadenopathy is present,
consider elective neck dissection
(comprehensive or selective, as appropriate).
Provide postoperative radiotherapy for all
patients except those with T1 or T2 tumors
of low-grade histology and clear margins.
© 2006 WebMD, Inc. All rights reserved.
2 HEAD AND NECK
Primary lymphoma of the salivary gland is uncommon, occur-
ring in fewer than 5% of patients with parotid masses.5 Suggestive
clinical features include (1) the development of a parotid mass in
a patient with a known history of malignant lymphoma, (2) the
occurrence of a parotid mass in a patient with an immune disor-
der (e.g., Sjögren syndrome, rheumatoid arthritis, or AIDS), (3)
the presence of a parotid mass in a patient with a previous diag-
nosis of benign lymphoepithelial lesion, (4) the finding of multiple
masses in one parotid gland or of masses in both parotid glands,
and (5) the association of a parotid mass with multiple enlarged
cervical lymph nodes unilaterally or bilaterally.6
Neoplastic Neoplastic masses may be present for years with-
out causing any symptoms. Benign salivary tumors are more com-
mon in younger persons, whereas malignant parotid lesions are
more common in the fifth and sixth decades of life.7 The classic
presentation of a benign parotid tumor is that of an asymptomatic
parotid mass that has been present for months to years. Benign
neoplasms of the parotid include pleomorphic adenoma, basal cell
adenoma, myoepithelioma,Warthin tumor, oncocytoma, and cystad-
enoma. The observation of rapid growth in a long-standing pleo-
morphic adenoma is suggestive of malignant transformation. In a
2005 study of 94 patients with pleomorphic adenoma, malignant
transformation to carcinoma was documented in 8.5% of cases.8
Rapid tumor growth, metastasis to lymph nodes, deep fixation,
and facial nerve weakness are all strongly suggestive of malignant
disease and are indicators of a poor prognosis.9 Although pain is
more often experienced by patients with benign conditions, it is also
reported by some patients with infiltrative malignant tumors. In
the latter patients, pain is another indicator of a poor prognosis.10
The presence of facial nerve palsy should raise the index of sus-
picion for malignancy. Occasionally, patients present with classic
Bell palsy. This condition is usually of viral origin, and most pa-
tients recover over time. If Bell palsy persists, however, further in-
vestigation is required, including imaging studies to rule out any
obvious parotid lesion. Facial palsy occurring in association with
parotitis and anterior uveitis is known as Heerfordt syndrome and
is often seen in patients with sarcoidosis.
PHYSICAL EXAMINATION
The physical examination should focus on the extent of the dis-
ease in the parotid, the neck, and the parapharynx; the localized
effects of the tumor (including trismus); and the motor or senso-
ry deficits resulting from neural invasion.
The mass is palpated to determine whether it is painless or
painful; whether it is soft, firm, hard, or cystic; and whether it is
mobile or fixed to deep tissue or skin.The skin of the scalp, the ear,
and the face is examined for lesions. The neck is palpated for
adenopathy. In the oral cavity, the ducts are examined for dis-
charge or saliva after the glands are milked.The pharyngeal wall is
examined for deviation, and the jaw is examined for trismus.
The parotid occupies a large area, starting from the zygoma and
extending to the upper portion of the neck and behind the
mandible to what is commonly called the tail of the parotid.
Occasionally, the parotid tissue extends behind the earlobe, in
which case it may be misdiagnosed preoperatively as a nonsalivary
pathologic condition. Accessory parotid tissue is present along
Stenson’s duct in approximately 21% of persons.11 Patients some-
times present with a tumor (most commonly, a benign mixed
tumor) of this accessory tissue.12 Attempts to excise such masses
locally must be avoided, because of the high risk of injury to
branches of the facial nerve.
ACS Surgery: Principles and Practice
2 PAROTID MASS — 3
The most common presentation of a parotid mass, whether
benign or malignant, is an asymptomatic swelling in the preauric-
ular or retromandibular region. Occasionally, patients present with
metastases to the intraparotid or periparotid lymph nodes. There
are approximately 17 to 20 lymph nodes in the substance of the
parotid and along its tail, and there may be a smaller number of
lymph nodes within the deep lobe of the gland. These lymph
nodes may be directly affected by metastatic tumors originating
from the anterior scalp or the temporal, periocular, or malar
regions. Especially with elderly patients, it is extremely crucial to
obtain a detailed history of any previously excised skin lesions,
some of which may have been squamous cell carcinomas (SCCs)
that metastasized to the periparotid nodes. Generally, such metas-
tasis involves multiple superficial lymph nodes and presents as dif-
fuse enlargement of the parotid parenchyma. With the massive
involvement of the parotid gland, facial nerve palsy is not uncom-
mon in this setting.The majority of metastases to the parotid gland
derive from cutaneous SCC or melanoma; however, metastatic
spread from the lung, the breast, and the kidney also is known to
occur.13
The location of the parotid mass is a very important diagnostic
factor. The classic presentation of a benign mixed tumor is as a
marblelike lesion in the parotid gland—a firm, mobile mass that
commonly originates in the superficial portion of the gland and
generally is not fixed to the deeper structures or to the skin.
Parotid tumors that originate in the deep lobe may present as a
vague, diffuse swelling behind the angle of the mandible; more
often, however, they present as a swelling of the parapharyngeal
area accompanied by medial displacement of the tonsil or the soft
palate.
Although physical examination of a parotid mass is a simple
process in itself, it should be accompanied by a thorough evalua-
tion of the head and neck that includes a detailed examination of
the oral cavity and the oropharyngeal, nasopharyngeal, hypopha-
ryngeal, and laryngopharyngeal areas. Occasionally, a tumor of the
oropharynx presents as cervical lymphadenopathy or as metastat-
ic disease in the tail of the parotid. In such cases, it may be diffi-
cult to determine whether the patient has a primary salivary gland
tumor or a metastatic lesion. The presence of any suspicious
pathologic condition in the oropharynx or the base of the tongue
is an indication for appropriate endoscopy and biopsy of the sus-
pected primary site.
Physical findings suggestive of malignancy include a large and
fixed mass, facial nerve weakness, lymph node metastasis, and
skin involvement; patients with advanced parotid malignancies
may present with trismus. Whereas patients with benign parotid
tumors rarely exhibit facial nerve weakness, approximately 12%
to 15% of patients with parotid malignancies have facial nerve
dysfunction at presentation.14 The most common causes of facial
nerve weakness in this setting are adenoid cystic carcinoma,
poorly differentiated carcinoma, and SCC. Primary SCC of the
parotid is quite rare, and a diagnosis of SCC in the gland should
lead one to suspect that a tumor has metastasized to the parotid
lymph nodes. Before the diagnosis of primary SCC of the paro-
tid is made, high-grade mucoepidermoid carcinoma and metasta-
tic SCC must be excluded.
The presence of cervical lymph node metastasis may direct
one’s attention to the parotid mass, though only about 20% of per-
sons with parotid malignancies actually have clinically apparent
cervical lymph node metastases at the time of initial presenta-
tion.10 The parotid tumors most commonly associated with
metastatic disease to the lymph nodes at presentation are high-
© 2006 WebMD, Inc. All rights reserved.
2 HEAD AND NECK
grade mucoepidermoid carcinoma, poorly differentiated carcino-
ma, and SCC. Lymph node metastases may also derive from high-
grade adenocarcinomas or malignant mixed tumors.
Some patients are totally asymptomatic, with the only signifi-
cant physical finding being a mass visible through the open mouth,
which is suggestive of either a deep-lobe parotid tumor or a para-
pharyngeal tumor.The majority of parotid tumors develop within
the superficial lobe of the parotid—not surprisingly, given that
between 80% and 90% of the parotid tissue is superficial to the
facial nerve. However, a significant minority of parotid masses—
about 10%—are found within the deep lobe. Most deep-lobe
parotid tumors are benign, in which case surgical treatment gen-
erally consists of a superficial parotidectomy with dissection and
preservation of the facial nerve, followed by removal of the tumor.
Occasionally, however, malignant deep-lobe parotid tumors do
occur. Such tumors frequently involve the facial nerve, and surgi-
cal treatment may require sacrifice of the facial nerve in select cir-
cumstances. Most patients who have undergone surgical treat-
ment of a malignant deep-lobe tumor will require postoperative
radiation therapy.
Investigative Studies
The majority of parotid masses can
easily be evaluated with a careful history
and a thorough physical examination.
Nevertheless, it sometimes happens that
even after these measures have been car-
ried out, there remains some clinical
uncertainty regarding whether the patho-
logic process is of parotid or of nonsali-
vary origin. A number of nonsalivary tumors (e.g., neurofibromas,
lipomas, lymphadenopathies, metastatic cutaneous lesions, and
lymphomas) are known to present in the parotid region on occa-
sion. These tumors may be difficult to evaluate clinically, and fur-
ther diagnostic studies may therefore be required.
IMAGING
Generally, parotid masses are imaged with either computed
tomography or magnetic resonance imaging.15 CT is superior to
MRI for evaluation of the bony structures, whereas MRI may be
more helpful in distinguishing between inflammatory conditions
and salivary neoplasms. CT scanning is indicated in patients with
diffuse enlargement of the parotid gland, tumor extension beyond
the superficial lobe, facial nerve weakness, trismus, or deep-lobe
parotid tumors that are difficult to evaluate clinically. If the parotid
mass appears to be fixed to the deeper structures, it is appropriate
to proceed with CT to evaluate the extent and parapharyngeal
extension of the disease. MRI is indicated in patients with facial
nerve paralysis. Occasionally, it may be necessary to perform both
CT and MRI. Both imaging methods are helpful and accurate in
distinguishing deep-lobe parotid tumors from other parapharyn-
geal masses. They are also useful for evaluating suspicious lymph
nodes and the periphery of the mass (specifically with respect to
determining whether the lesion is encapsulated or has irregular
borders).
Ultrasonography can be useful for determining the location of
the lesion and for guiding fine-needle aspiration (FNA) biopsy. In
the past, technetium-99m scanning was commonly employed for
the diagnosis of oncocytoma and Warthin tumor.16
Various other diagnostic studies are available for evaluation of
parotid masses. At one time, sialography was commonly employed
to assess patients with suspected salivary stones, as well as to eval-
ACS Surgery: Principles and Practice
2 PAROTID MASS — 4
uate the ductal arrangements in patients with chronic sialoadeni-
tis. Currently, however, sialography is rarely used, both because
there is a significant possibility of an infectious flare-up and
because the study actually yields only minimal information. In the
early 1980s, CT sialography became popular for a time; however,
it was quite a complicated procedure, and clinicians eventually
found that the information it yielded could easily be obtained from
spiral (helical) CT. Occasionally, surface-coil MRI may be helpful
for evaluating parotid masses deriving from subcutaneous process-
es. Sialoendoscopy has generated considerable interest, especially
in Europe and Germany17; however, this sophisticated technology
has not yet entered everyday practice. Although sialoendoscopy
may be of some value in the assessment of salivary stone disease
or chronic sialectasis, it is rarely performed in the United States at
present, and its eventual role in the evaluation of parotid masses
remains to be determined.
For a classic benign mixed tumor presenting in the form of a
small nodule in the superficial lobe of the parotid gland, imaging
is not required.
Currently, the role of positron emission tomography (PET) in
the initial evaluation of a parotid mass remains undefined. This
modality may, however, be of some value in the evaluation of sus-
pected recurrent parotid cancers, lymph node metastases, or dis-
tant metastases.
FINE-NEEDLE ASPIRATION BIOPSY
Routine use of FNA biopsy in the evaluation of a parotid mass
[see Table 1] continues to be controversial. One reason for the
controversy is that cytologic evaluation is difficult. Another is
that the extent of surgical treatment can easily be defined by
means of the clinical assessment. The main argument against
routine use of FNA biopsy is based on the standard approach to
most parotid masses, which is a superficial parotidectomy that
includes identification and preservation of the facial nerve.
Nevertheless, FNA biopsy can be quite helpful, especially for the
purposes of preoperative consultation with patients regarding
the suspected pathologic process and the extent of surgical ther-
apy. FNA biopsy has an overall accuracy that exceeds 90%,18,19
and it is considered a good investigational tool as long as it is
used in the appropriate clinical context.
In the case of a classic benign mixed tumor, which presents as
a mobile, confined, superficial nodule in the parotid gland, FNA
biopsy is not required for further treatment. However, in cases
where the clinical picture is not definitive and one cannot deter-
mine whether the pathologic process is of parotid origin or not,
FNA biopsy is extremely important. Besides distinguishing be-
tween benign and malignant conditions, FNA biopsy can also
distinguish between salivary and nonsalivary processes [see Table
Table 1 Uses of FNA Biopsy in Evaluation
of Parotid Mass
To identify suspected malignancy
To diagnose metastatic carcinoma
To identify suspected lymphoma
To distinguish between salivary and nonsalivary lesions
To facilitate conservative management of Warthin tumor or pleomorphic
adenoma in a poor-risk patient
To confirm preoperatively suspected malignancy in a patient with facial
palsy
To evaluate bilateral tumors
© 2006 WebMD, Inc. All rights reserved. ACS Surgery: Principles and Practice
2 HEAD AND NECK 2 PAROTID MASS — 5

Table 2 Salivary and Nonsalivary Pathologic Table 3 American Joint Committee on

Processes Distinguished by FNA Biopsy Cancer TNM Clinical Classification of Major
Salivary Gland Tumors
Benign
Mixed tumor
TX: Primary tumor cannot be assessed
Warthin tumor
T0: No evidence of primary tumor
Malignant
T1: Tumor ≤ 2 cm in greatest dimension without
Primary salivary gland cancer extraparenchymal extension
Salivary processes
Metastatic disease in salivary gland T2: Tumor > 2 cm but ≤ 4 cm in greatest dimen-
Cystic adenoma Primary tumor (T) sion without extraparenchymal extension
SCC T3: Tumor having extraparenchymal extension
Adenocarcinoma without seventh nerve involvement and/or >
Melanoma 4 cm but ≤ 6 cm in greatest dimension
T4: Tumor invades base of skull, seventh nerve,
Lipoma and/or > 6 cm in greatest dimension
Sebaceous cyst
NX: Regional lymph nodes cannot be assessed
Lymph node pathology
Nonsalivary processes N0: No regional lymph node metastasis
Benign melanoma
N1: Metastasis in a single ipsilateral lymph node,
Metastatic cancer ≤ 3 cm in greatest dimension
Lymphoma N2: Metastasis in a single ipsilateral lymph node,
> 3 cm but ≤ 6 cm in greatest dimension; or
in multiple ipsilateral lymph nodes, none > 6
cm in greatest dimension; or in bilateral or
2].20 A variety of different lymph node pathologies, benign contralateral lymph nodes, none > 6 cm in
parotid tumors, and even suspected malignant parotid tumors Regional lymph nodes (N) greatest dimension
can be differentiated by means of FNA biopsy. Furthermore, N2a: Metastasis in a single ipsilateral lymph
lymphoepithelial lesions of the parotid, benign mixed tumors, node > 3 cm but ≤ 6 cm in greatest
dimension
and Warthin tumors are easily diagnosed with this procedure. N2b: Metastasis in multiple ipsilateral lymph
FNA biopsy is particularly useful when a parotid mass is likely nodes, none > 6 cm in greatest
to be the result of metastasis. dimension
Occasionally, in an elderly person whose overall physical con- N2c: Metastasis in bilateral or contralateral
lymph nodes, none > 6 cm in greatest
dition is poor, a conservative approach can be taken when a dimension
Warthin tumor is diagnosed by means of FNA biopsy. Similarly, N3: Metastasis in a lymph node > 6 cm in great-
in a person with a long-standing benign mixed tumor, observa- est dimension
tion may be appropriate if the patient is not a candidate for sur- MX: Distant metastasis cannot be assessed
gical intervention and if FNA biopsy confirms that the lesion is Distant metastasis (M) M0: No distant metastasis
benign. M1: Distant metastasis
FNA biopsy findings that suggest lymphoma may help one
avoid unnecessary parotidectomy and risk to the facial nerve.
Often, it is hard to achieve a definitive diagnosis of lymphoma by Staging and Prognosis
means of FNA biopsy alone. In such cases, core biopsy or open
biopsy can be performed to establish the diagnosis. Core biopsy of For cancers of the parotid gland (as well as those of other major
a parotid mass is a difficult procedure (unless the mass is very large salivary glands), staging is accomplished by means of the familiar
and very superficial), and it is generally contraindicated on the tumor-node-metastasis (TNM) system developed by the Ameri-
grounds that it may cause bleeding or facial nerve injury. Never- can Joint Committee on Cancer (AJCC) and the International
theless, if core biopsy can be performed safely, it can be a good Union Against Cancer (UICC) [see Tables 3 and 4].23
choice in cases where lymphoma is suspected on the basis of FNA The prognostic factors in the management of parotid gland
biopsy.21 Open incisional biopsy can also be performed safely tumors must be understood in relation to the stage the disease has
when done in conjunction with continuous monitoring of the reached, the need for postoperative radiation therapy, and the
facial nerve.22 overall long-term outcome [see Table 5]. Such factors include age
Benign lymphoepithelial lesions related to HIV disease are
readily diagnosed by means of FNA biopsy, especially if they are
multiply recurrent cystic lesions in the tail of the parotid or if they Table 4 American Joint Committee on Cancer
occur bilaterally. In general, HIV-related pathology is quite easy to
Staging System for Major Salivary Gland Tumors
diagnose with FNA; HIV-infected patients with benign lym-
phoepithelial lesions may be treated by providing appropriate
Stage T N M
management of the underlying illness.
The crucial points for clinicians with respect to FNA biopsy in Stage I T1, T2 N0 M0
the setting of a parotid mass are (1) that this investigative study will
not make a definitive diagnosis of parotid malignancy and (2) that Stage II T3 N0 M0
one therefore should not make decisions about how to manage the Stage III T1, T2 N1 M0
facial nerve solely on the basis of an FNA-suggested malignant
T4 N0 M0
diagnosis. Any decisions regarding the approach to the facial nerve
T3, T4 N1 M0
should also be based on preoperative assessment of facial nerve Stage IV
Any T N2, N3 M0
function and intraoperative evaluation of the nerve in relation to Any T Any N M1
the tumor.
© 2006 WebMD, Inc. All rights reserved.
2 HEAD AND NECK
Table 5 Prognostic Factors for Salivary
Gland Tumors
Age at diagnosis Facial nerve dysfunction
Pain at presentation Perineural growth
T stage Positive surgical margins
N stage Soft tissue invasion
Skin invasion Treatment type
at diagnosis, pain at presentation, TNM staging, skin invasion,
facial nerve dysfunction, perineural growth of the primary tumor,
positive surgical margins in the final pathology report, soft tissue
invasion by the primary tumor, treatment type, and extranodal
spread of the metastatic disease in the neck. To make definitive
decisions regarding treatment, it is necessary to analyze these
prognostic factors critically in individual patients. An example of
such critical analysis is the prognostic index devised by the Dutch
Head and Neck Cooperative Group for patients with parotid can-
cer.24,25 In this index, a weighted combination of the parameters of
age, pain, tumor size, nodal stage, skin invasion, facial nerve dys-
function, perineural growth, and positive surgical margins is
employed to compute a prognostic score. The score is then used
to assign patients to one of four groups, each of which is associat-
ed with an expected recurrence-free percentage.
Management
Treatment of a parotid mass depends
on the nature and extent of the lesion [see
Table 6]. Malignant parotid masses are
treated surgically according to established
oncologic principles [see Surgical Therapy,
below], with postoperative radiation thera-
py added as necessary [see Radiation
Therapy, below]. Generally, benign paro-
tid masses are managed surgically as well, with exploration of the
parotid gland, evaluation of the neoplasm, and appropriate
parotidectomy with identification and preservation of the facial
nerve and its branches. In the case of a suspected benign mixed
tumor, enucleation is contraindicated because of the possibility of
tumor spillage, incomplete removal of the tumor, injury to the
capsule and resultant seeding of the tumor into the parotid tissue,
or inadvertent injury to the branches of the facial nerve. Enuclea-
tion of such a tumor is very likely to result in local recurrence, which
invariably is much more difficult to manage than the original
lesion was and poses a high risk of injury to the facial nerve.
SURGICAL THERAPY
Parotidectomy with or without Facial Nerve Reconstruction
The minimum surgical procedure for a parotid mass is superfi-
cial parotidectomy with identification and preservation of the
facial nerve [see 2:6 Parotidectomy]. Subtotal parotidectomy may be
required for larger tumors that involve the deep lobe of the parotid
gland; however, true total parotidectomy with preservation of the
facial nerve is almost impossible, because of the parotid gland tis-
sues surrounding the nerve. If the tumor involves the facial nerve
and is directly infiltrating into it, a diagnosis of malignancy should
be explored, and only if the diagnosis is confirmed should the
facial nerve be sacrificed. Preoperative facial nerve weakness gen-
erally indicates that the tumor is involving the nerve, in which case
ACS Surgery: Principles and Practice
2 PAROTID MASS — 6
due consideration should be given to the sacrifice and subsequent
reconstruction of this structure.
Reconstruction of the facial nerve can be performed with a
nerve graft from the greater auricular nerve, from the sural
nerve in the leg, or from the ansa hypoglossi. In view of the
technical complexity of nerve grafting, preoperative consulta-
tion with a plastic surgeon may be necessary. The functional
results of nerve grafting vary considerably, depending on the
age of the patient, the extent of the disease, and the identifica-
tion of and appropriate anastomosis to the peripheral branches
of the facial nerve. If postoperative radiation therapy is envi-
sioned, its potential deleterious effects on nerve regeneration
should be kept in mind.
If the tumor involves only an isolated branch of the facial nerve,
one may opt for selective sacrifice of that branch, along with nerve
grafting. If the tumor extends beyond the parotid gland and
involves the infratemporal fossa, the ascending ramus of the
mandible, or the mastoid process, a much more extensive surgical
procedure (e.g., composite resection, lateral temporal bone resec-
tion, or radical parotidectomy with sacrifice of the entire facial
nerve) becomes necessary. Such patients invariably require post-
operative radiation therapy [see Radiation Therapy, below]. How-
ever, in the majority of patients who present with an isolated paro-
tid mass and a functioning facial nerve, every attempt should be
made to preserve the nerve.26 It is rarely necessary to sacrifice a
functioning facial nerve: the only indication for doing so is a situ-
ation in which the entire tumor cannot be resected without sacri-
fice of the main trunk or the branches of the facial nerve and there
is concern about leaving any gross tumor behind.
Intraoperative Frozen-Section Examination
The role of intraoperative frozen-section examination in the
evaluation of a parotid mass, like that of FNA biopsy, is the sub-
ject of considerable debate. Nevertheless, frozen-section examina-
tion has been found to be useful for distinguishing salivary pro-
cesses from nonsalivary processes and benign disease from malig-
nant disease. In 80% to 90% of cases, the findings from intraop-
erative frozen-section examination correlate with the final patho-
logic diagnosis.27 This study is also helpful in making a definitive
diagnosis of Warthin tumor. If frozen-section examination shows a
benign mixed tumor and this finding agrees with one’s clinical
judgment, lateral superficial parotidectomy should be sufficient. If
frozen-section examination shows high-grade mucoepidermoid
carcinoma, selective neck dissection may be considered (mainly
for staging purposes, to determine whether any of the deep jugu-
lar nodes are positive). If frozen-section examination provides a
definitive diagnosis of malignancy, further decisions about the
extent of parotidectomy and possible selective neck dissection can
be made accordingly; if not, the procedure originally planned can
be performed, with any further interventions (if required) dictated
by the final pathologic diagnosis. Obviously, the decision whether
to sacrifice the facial nerve must not be based solely on whether
the frozen section shows a benign or a malignant process.
Table 6 Principles of Treatment of Parotid Tumors
Adequate local excision of tumor, based on extent of primary lesion
Preservation of facial nerve if possible
Elective neck dissection reserved for selected patients
Postoperative radiotherapy when indicated (in appropriate fields)
Prognosis determined primarily by stage and grade of tumor
© 2006 WebMD, Inc. All rights reserved.
2 HEAD AND NECK
Table 7 Indications for Postoperative Radiation
Therapy for Parotid Cancer
Aggressive, highly malignant tumor
Invasion of adjacent tissues outside parotid capsule
Regional lymph node metastases
Deep-lobe cancer
Gross residual tumor after resection
Recurrent tumor after resection
Invasion of facial nerve by tumor
Neck Dissection
Overall, about 20% of patients with malignant parotid tumors
present with clinically detectable cervical lymphadenopathy
(cN+).10 There is wide agreement that these patients require either
a comprehensive or a modified neck dissection [see 2:7 Neck
Dissection], depending on the extent of the disease, but there con-
tinues to be controversy regarding the management of patients
with salivary malignancies who have no clinically detectable cervi-
cal lymphadenopathy (cN0). In one study, approximately 14% of
the patients were in cN+ status; however, approximately 12% were
in cN0 status but presented with pathologically positive nodes
(pN+).28 In view of the low frequency of occult metastasis in the
group as a whole, the investigators generally did not recommend
routine elective treatment of the neck. They did find that certain
histologic grades were associated with a higher incidence of
metastatic disease to the neck nodes: the incidence of occult
metastasis was about 49% in patients with high-grade lesions,
compared with 7% in those with intermediate-grade or low-grade
lesions. In addition, the incidence of having occult metastatic dis-
ease was more than 20% in patients with tumors larger than 4 cm,
compared with 4% in those with smaller tumors.
The incidence of lymph node metastasis is affected not only by
the size and histologic grade of the tumor but also by the histologic
type, the primary tumor stage, the presence of facial nerve palsy,
the patient’s age, the extraparotid extension of the disease, and the
degree of perilymphatic invasion.29 In a multivariate analysis, the
variables that showed the highest correlation with the incidence of
lymph node metastasis were the histologic type (i.e., adenocarci-
noma, undifferentiated carcinoma, high-grade mucoepidermoid
carcinoma, SCC, or salivary duct carcinoma) and the T stage.30
Thus, elective neck dissection may be considered in patients
with advanced-stage primary tumors, those whose tumors are of
high histologic grades, and those whose tumors are of certain spe-
cific histologic types. A selective neck dissection may be performed
to remove the lymph nodes of the submandibular triangle, level II,
level III, and the upper part of level V for the purposes of staging.29
However, a comprehensive neck dissection that encompasses lev-
els I through V may be necessary in patients who present with clin-
ically obvious cervical metastases.
Discussion
Implications of Histopathologic Classification of Parotid
Gland Cancer
Alhough considerable controversy and debate continue to sur-
round the histopathologic classification of malignant parotid
tumors, most clinicians currently prefer either the classification
system of the Armed Forces Institute of Pathology35 or that of the
ACS Surgery: Principles and Practice
2 PAROTID MASS — 7
100
75
Percent
50
25
0 5 10
Time (Years)
Stage I, II Stage I, II with RT
Stage III, IV Stage III, IV with RT
Figure 1 Depicted is the impact of postoperative radiation therapy
(RT) on overall outcome for patients with stage I or II tumors and
patients with stage III or IV tumors.
RADIATION THERAPY
Patients who present with advanced-stage (stage III or IV) dis-
ease, a large primary tumor, close margins, perineural spread, soft
tissue extension, facial nerve dysfunction, or cervical lymph node
metastasis invariably require postoperative radiation therapy [see
Table 7].31,32 In general, this means that postoperative radiation
therapy is indicated for all patients except those with T1 or T2
malignant tumors of low-grade histology and clear margins.Thus,
the decision whether to employ such therapy depends largely on
the intraoperative findings and the final pathology report. A 1990
analysis showed that postoperative radiation therapy had a major
impact on overall outcome in patients with stage III or IV tumors
but conferred no statistically significant benefit on patients with
stage I or II tumors [see Figure 1].33
Currently, there is substantial interest in the potential role of
neutron therapy as a primary treatment modality for parotid
malignancies, especially advanced inoperable parotid cancers and
adenoid cystic carcinomas. A group from the University of
Washington demonstrated that neutron therapy exerted a benefi-
cial effect when used as the sole treatment of advanced parotid
cancers.34 Although these results are extremely promising, the
patients treated with this modality clearly experienced an
increased incidence of complications. Nevertheless, for patients
with inoperable parotid cancer, neutron therapy may be the best
option currently available.
World Health Organization.36 The most common types of parotid
tumor are mucoepidermoid carcinoma, adenoid cystic carcinoma,
adenocarcinoma, malignant mixed tumor, acinic cell carcinoma,
and primary SCC [see Figure 2].
As noted (see above), primary SCC of the parotid gland is quite
rare, and most diagnoses of parotid SCC represent skin cancer
© 2006 WebMD, Inc. All rights reserved. ACS Surgery: Principles and Practice
2 HEAD AND NECK 2 PAROTID MASS — 8

cystic carcinoma is low; however, the incidence of distant metasta-

sis (especially pulmonary metastasis) appears to be high.41 It is
noteworthy that even when adenoid cystic carcinoma patients have
Other pulmonary metastases, they tend to do remarkably well. Quite
often, the metastatic disease in the lungs remains dormant for
months or even years. At present, the role of chemotherapy in the
Adenocarcinoma management of adenoid cystic carcinoma and parotid tumors is
supported only by anecdotal evidence and remains investigational.

Mucoepidermoid Principles of Facial Reanimation

Adenoid
Cystic
Acinic
Cell
Malignant
Mixed
Squamous
Figure 2 Shown are the approximate relative frequencies of the
most common types of parotid gland tumors.
that has metastasized to the periparotid lymph nodes. Primary
SCC has a high malignant potential, and radical surgical extirpa-
tion (with preservation of the facial nerve when possible), followed
by planned postoperative radiotherapy, is the treatment of
choice.37
Mucoepidermoid carcinomas are best divided into low-grade,
intermediate-grade, and high-grade tumors.38 For high-grade
tumors, selective node dissection may be appropriate, with due
consideration given to postoperative radiation therapy. For the
majority of low-grade tumors—provided that they are properly
excised with appropriate superficial parotidectomy—postoperative
radiation therapy is unnecessary, because the incidence of local
recurrence is lower than 5%.
Adenoid cystic carcinoma is a unique salivary gland tumor with
a classic Swiss-cheese appearance under the microscope.There is a
very high incidence of perineural spread with skip metastasis along
the facial nerve and its branches, and the incidence rises with high-
er T stages.39 The incidence of local recurrence is also very high,
and thus, postoperative radiation therapy should be provided to
patients who are at high risk for relapse (i.e., those with close or
positive margins and those with perineural invasion). Such therapy
appears to reduce the incidence of local recurrence.40 The inci-
dence of cervical lymph node metastasis in patients with adenoid
Every surgeon who performs parotid surgery, especially surgery
for parotid cancer, should be familiar with the principles of facial
reanimation. If the facial nerve dysfunction is recognized before
the operation, appropriate arrangements may be made for plastic
surgical consultation and facial nerve grafting. If the proximal
stump of the facial nerve can be identified and the peripheral
branches detected at the time of the operation, a nerve graft repair
can be performed. The main donor nerves used in facial nerve
grafting are the greater auricular nerve, the ansa hypoglossi, and
the sural nerve. Of these, the greater auricular nerve is the pre-
ferred source for a graft: harvesting is relatively easy, the diameter
matches that of the facial nerve, and the arborization of the distal
branches allows for a greater number of facial nerve grafts.42 The
use of loupes or a microscope helps in the placement of the 9-0
nylon stitches employed in facial nerve grafting.
Regeneration of the facial nerve may take 3 to 6 months.There
is some controversy regarding whether postoperative radiation
therapy has a beneficial effect on functional outcome after nerve
grafting: some studies cite detrimental effects,43 whereas others
report adequate functional outcomes.42,44 In any case, if it is feasi-
ble to perform nerve grafting, every attempt should be made to do
so. Currently, hypoglossal nerve transfer is rarely performed,45
because various effective alternatives (e.g., fascia lata slings and
Gore-Tex slings) are available. A consultation with a facial plastic
surgeon may be quite helpful in the management of patients with
total facial nerve palsy.
One of the most important considerations in addressing facial
nerve paralysis is how to prevent exposure keratopathy and other
ocular complications. Placement of a gold weight or a palpebral
spring on the upper eyelid may be considered as a primary reha-
bilitative measure aimed at preventing corneal ulceration and
opacification.46 In the past, lateral tarsorrhaphy was commonly
employed for this purpose, but currently, as a consequence of the
superior results obtained with the gold weight and the palpebral
spring, it is rarely performed. Other, simpler measures for pre-
venting or minimizing ocular complications include the use of arti-
ficial tears and an eye patch during the day and the use of oint-
ment with proper taping to keep the eyelid closed at night.

References

1. Beckhardt RN,Weber RS, Zane R, et al: Minor sali-
vary gland tumors of the palate: clinical and patho-
logic correlates of outcome. Laryngoscope 105:1155,
1995
2. Eneroth CM: Salivary gland tumors in the parotid
gland, submandibular gland and the palate region.
Cancer 27:1415, 1971
3. Spiro RH: Salivary neoplasms: overview of a 35-
year experience with 2,807 patients. Head Neck
Surg 8:177, 1986
4. Fu YS, Wenig BM, Abemayor E, et al: Head and
Neck Pathology With Clinical Correlations.
Churchill Livingstone, New York, 2001, p 234
5. Batsakis JG: Primary lymphomas of the major sali-
vary glands. Ann Otol Rhinol Laryngol 95:107,
1986
6. Barnes L, Myers EN, Prokopakis EP: Primary malig-
nant lymphoma of the parotid gland. Arch Otolaryn-
gol Head Neck Surg 124:573, 1988
7. Kane WJ, McCaffrey TV, Olsen KD, et al: Primary
parotid malignancies. A clinical and pathologic re-
view. Arch Otolaryngol Head Neck Surg 117:307,
1991
8. Friedrich RE, Li L, Knop J, et al: Pleomorphic ade-
noma of the salivary glands: analysis of 94 patients.
Anticancer Res 25:1703, 2005
9. Wong DS: Signs and symptoms of malignant pa-
rotid tumours: an objective assessment. J R Coll Surg
Edinb 46:91, 2001
10. Spiro RH, Huvos AG, Strong EWL: Cancer of the
parotid gland: a clinicopathologic study of 288 pri-
mary cases. Am J Surg 130:452, 1975
11. Frommer J:The human accessory parotid gland: its
incidence, nature, and significance. Oral Surg Oral
Med Oral Pathol 43:671, 1977
12. Rodino W, Shaha AR: Surgical management of
accessory parotid tumors. J Surg Oncol 54:153,
1993
© 2006 WebMD, Inc. All rights reserved.
2 HEAD AND NECK
13. Batsakis JG, Bautina E: Metastases to major salivary
glands. Ann Otol Rhinol Laryngol 99:501, 1990
14. O’Brien CJ, Fracs MS, Adams JR: Surgical man-
agement of the facial nerve in the presence of malig-
nancy about the face. Curr Opin Otolaryngol Head
Neck Surg 9:90, 2001
15. Rabinov JD: Imaging of salivary gland pathology.
Radiol Clin North Am 38:1047, 2000
16. Higashi T, Murahashi H, Ikuta H, et al: Identifica-
tion of Warthin’s tumor with technetium-99m per-
technetate. Clin Nucl Med 12:796, 1987
17. Gundlach P, Hopf J, Linnarz M: Introduction of a
new diagnostic procedure: salivary duct endoscopy
(sialendoscopy) clinical evaluation of sialendoscopy,
sialography, and x-ray imaging. Endosc Surg Allied
Technol 2:294, 1994
18. Qizilbash AH, Sianos J,Young JE, et al: Fine needle
aspiration biopsy cytology of major salivary glands.
Acta Cytol 29:503, 1985
19. Stewart CJ, MacKenzie K, McGarry GW, et al:
Fine-needle aspiration cytology of salivary gland: a
review of 341 cases. Diagn Cytopathol 22:139,
2000
20. Shaha AR, Webber C, DiMaio T, et al: Needle aspi-
ration biopsy in salivary gland lesions. Am J Surg
160:373, 1990
21. Kesse KW, Manjaly G,Violaris N, et al: Ultrasound-
guided biopsy in the evaluation of focal lesions and
diffuse swelling of the parotid gland. Br J Oral
Maxillofac Surg 40:384, 2002
22. Gross M, Ben-Yaacov A, Rund D, et al: Role of
open incisional biopsy in parotid tumors. Acta Oto-
laryngol 124:758, 2004
23. AJCC Cancer Staging Manual, 6th edition.
Springer-Verlag, New York, 2002
24. Vander Poorten VL, Balm AJ, Hilgers FJ, et al: The
development of a prognostic score for patients with
parotid carcinoma. Cancer 85:2057, 1999
25. Vander Poorten VL, Hart AA, van der Laan BF, et
al: Prognostic index for patients with parotid carci-
ACS Surgery: Principles and Practice
noma: external validation using the nationwide
1985–1994 Dutch Head and Neck Oncology
Cooperative Group database. Cancer 97:1453,
2003
26. Nussbaum M, Bortikner D: Facial nerve preserva-
tion in parotid carcinoma. Bull NY Acad Med
62:862, 1986
27. Heller KS, Attie JN, Dubner S: Accuracy of frozen
section in the evaluation of salivary tumors. Am J
Surg 166:424, 1993
28. Armstrong JG, Harrison LB, Thaler HT, et al: The
indications for elective treatment of the neck in can-
cer of the major salivary glands. Cancer 69:615,
1992
29. Ferlito A, Shaha AR, Rinaldo A, et al: Management
of clinically negative cervical lymph nodes in pa-
tients with malignant neoplasms of the parotid
gland. ORL J Otorhinolaryngol Relat Spec 63:123,
2001
30. Regis De Brito Santos I, Kowalski LP, Cavalcante
De Araujo V, et al: Multivariate analysis of risk fac-
tors for neck metastases in surgically treated parotid
carcinomas. Arch Otolaryngol Head Neck Surg
127:56, 2001
31. Tullio A, Marchetti C, Sesenna E, et al: Treatment
of carcinoma of the parotid gland: the results of a
multicenter study. J Oral Maxillofac Surg 59:263,
2001
32. Harrison LB, Armstrong JG, Spiro RH, et al:
Postoperative radiation therapy for major salivary
gland malignancies. J Surg Oncol 45:52, 1990
33. Armstrong JG, Harrison LB, Spiro RH, et al:
Malignant tumors of major salivary gland origin: a
matched-pair analysis of the role of combined sur-
gery and postoperative radiotherapy. Arch Otolaryn-
gol Head Neck Surg 116:290, 1990
34. Laramore GE, Krall JM, Griffin TW, et al: Neutron
versus photon irradiation for unresectable salivary
gland tumors: final report of an RTOG-MRC ran-
domized clinical trial. Radiation Therapy Oncology
Group. Medical Research Council. Int J Radiat
2 PAROTID MASS — 9
Oncol Biol Phys 27:235, 1993
35. Ellis GL, Auclair PL: Tumors of the Salivary
Glands. Atlas of Tumor Pathology, series 3, fascicle
17. Armed Forces Institute of Pathology, Washing-
ton, DC, 1996
36. Seifert G, Sobin LH: The World Health Organiza-
tion’s histological classification of salivary gland
tumors: a commentary on the second edition. Can-
cer 70:379, 1992
37. Shemen LJ, Huvos AG, Spiro RH: Squamous cell
carcinoma of salivary gland origin. Head Neck Surg
9:235, 1987
38. Batsakis JG, Luna MA: Histopathologic grading of
salivary gland neoplasms: I. Mucoepidermoid carci-
nomas. Ann Otol Rhinol Laryngol 99:835, 1990
39. Vrielinck LJ, Ostyn F, van Damme B, et al:The sig-
nificance of perineural spread in adenoid cystic car-
cinoma of the major and minor salivary glands. Int
J Oral Maxillofac Surg 17:190, 1988
40. Vikram B, Strong EW, Shah JP, et al: Radiation
therapy in adenoid-cystic carcinoma. Int J Radiat
Oncol Biol Phys 10:221, 1984
41. Spiro RH: Distant metastasis in adenoid cystic car-
cinoma of salivary origin. Am J Surg 174:495, 1997
42. Reddy PG, Arden RL, Mathog RH: Facial nerve
rehabilitation after radical parotidectomy. Laryn-
goscope 109:894, 1999
43. Pillsbury HC, Fisch U: Extratemporal facial nerve
grafting and radiotherapy. Arch Otolaryngol 105:
441, 1979
44. McGuirt WF, McCabe BF: Effect of radiation ther-
apy on facial nerve cable autografts. Laryngoscope
87:415, 1977
45. Conley J, Baker DC: Hypoglossal-facial nerve anas-
tomosis for reinnervation of the paralyzed face. Plast
Reconstr Surg 63:63, 1979
46. Levine RE, Shapiro JP: Reanimation of the para-
lyzed eyelid with the enhanced palpebral spring or
the gold weight: modern replacements for tarsor-
rhaphy. Facial Plast Surg 16:325, 2000